Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-467 in Relapsed/Refractory Multiple Myeloma and Acute Myeloid Leukemia (Japan)
jRCT2080225038Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jan 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of abbv-467 in multiple myeloma (MM) and acute myeloid leukemia (AML), sponsored by AbbVie Inc. Primary endpoint: Safety and tolerability of ABBV-467. Started Jan 2020; status: terminated.
02
Drugs
abbv-467
03
Conditions
multiple myeloma (MM)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2080225038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225038.